Seeking partners such as NGOs, academic institutions, and companies to expand and accelerate our portfolio of drugs for neglected diseases, including emerging and tropical infectious diseases.
Charles Bailey
Partnering tabs - Core Therapeutic Areas
Novartis is uniquely diversified across therapy areas with exposure to cutting-edge technology platforms.
Looking for truly differentiating first or best-in-class treatments in:
- Heart Failure, Hypertension and Atrial Fibrillation
- Atherosclerosis and multiple CV risk factor management
- Metabolic (including Obesity)
Thierry Droz-Georget
Looking for truly differentiating first or best-in-class treatments in:
- Rheumatology
- Dermatology
- Disease modifying Osteoarthritis
- Nucleic acid sensing and Inflammasome
- Tolerance induction
- Allergy
Dominic Ehrismann
Looking for truly differentiating first or best-in-class treatments in:
- Neurodegeneration and Neuroinflammation
- Pediatric Neurological Diseases
- Psychiatry
Chi-Chi Zhu
Looking for truly differentiating first or best-in-class treatments in:
- Around Radioligand Therapies (RLT), including novel targets and advanced programs complementary to current pipeline and disease focus, isotopes and chelators for tumor specific RLT delivery
- Targeted Therapies. Novel targets complementary to pipeline / portfolio, addressing unmet needs in breast, lung, prostate, CRC, and pancreatic malignancies
- Immuno-oncology. Novel mechanisms complementary to anti-PD-1 or addressing unmet needs in breast, lung, CRC, prostate, and pancreatic malignancies
Markus Werner
Looking for truly differentiating first or best-in-class treatments:
- Targeted Therapies as well as
- Immuno-oncology based approaches with novel mechanisms that are complementary to our internal portfolio and pipeline addressing unmet needs in heme malignancies
- Celle & Gene. Novel T cell-based cell therapies to expand CART portfolio including solid tumors and leverage internal T-ChargeTM platform in deal-making. Advance from ex vivo HSC and CART therapy to in vivo gene therapy
Markus Werner
